Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering
July 19, 2019 05:40 ET
|
Genmab A/S
Company Announcement The 15% over-allotment option in connection with Genmab's initial public offering of American Depositary Shares in the United States and listing on the Nasdaq Global Select...
Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab
July 19, 2019 03:54 ET
|
Genmab A/S
Media Release Copenhagen, Denmark; July 19, 2019 Extension of marketing authorization submitted to European Medicines Agency for subcutaneous formulation of daratumumabSubmission based on data from...
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
July 17, 2019 20:30 ET
|
Genmab A/S
Company Announcement Genmab has today announced the pricing of its initial public offering of ADSs and the listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB”Genmab has...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019
July 16, 2019 06:44 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2019 totaled USD 774 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab
July 12, 2019 11:43 ET
|
Genmab A/S
Company Announcement BLA submitted to U.S. FDA for subcutaneous formulation of daratumumabSubmission based on data from Phase III COLUMBA and Phase II PLEIADES studies Copenhagen, Denmark; July 12,...
Genmab and BliNK Biomedical Enter into Commercial License Agreement
July 12, 2019 06:00 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, July 12, 2019 Genmab and BliNK Biomedical have entered into a commercial license agreement to develop novel bispecific therapeutics based on BliNK Biomedical’s...
Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States
July 09, 2019 06:22 ET
|
Genmab A/S
Company Announcement Genmab A/S has today commenced a public offering of American Depositary Shares (“ADSs”) and has filed a preliminary prospectus relating to the offeringGenmab A/S has applied for...
Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide, Bortezomib, and Dexamethasone
July 08, 2019 15:24 ET
|
Genmab A/S
Company Announcement Topline data from the randomized Phase II GRIFFIN study in transplant eligible, newly diagnosed patients with multiple myeloma treated with daratumumab in combination with...
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
June 27, 2019 13:22 ET
|
Genmab A/S
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are...
Major Shareholder Announcement
June 25, 2019 13:56 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 25, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish...